Fritextsökning
Artiklar per år
Innehållstyper
-
Årets opinionsartiklar 2023
Nu lider 2023 mot sitt slut. Här är några av krönikorna, debattartiklarna och ledarna från det gångna året från Life Science Sweden och systertidningarna Medtech Magazine och Fokus Hjälpmedel.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significance level. But what does that mean? Read Ingrid Lönnstedt´s column to learn more.
-
Julefrid ger läsetid – 10 artikeltips från redaktionen
När julstöket är avklarat, magen fått sitt och släkten avlägsnat sig lägger sig den stora friden – och kanske vaknar läslusten?
-
Patrik Sundström blir ordinarie vd för Inera
Sveriges Kommuner och Regioners digitaliseringsbolag Ineras har nu utsett en vd. Det blir nuvarande tillförordnade vd Patrik Sundström.
-
The International Vaccine Institute’s office in Sweden is expanding
The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched, says Anh Wartel, Head of the office.
-
Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas
Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in which we can see some long-awaited positive developments.
-
Mathias Uhlén’s protein atlas is recognised as a global resource
The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark and an opportunity for additional collaborations.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
A vaccine the world is waiting for: “It can change the lives of many”
A Solna laboratory is developing a vaccine that could save the lives of countless children in low- and middle-income countries. “Working on something that can make a difference for many people is important to me,” says Christine Hägglund, Laboratory Manager.
-
Business Sweden: “Companies have a lot to offer in data-driven precision medicine”
Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.
-
Produkter för in vitro-diagnostik ska utvärderas hos Rise
Svenska Rise har utsetts till referenslaboratorium av EU-kommissionen för vissa typer av medicintekniska produkter. Hos det statliga forskningsinstitutet kommer produkter för in vitro-diagnostik att utvärderas för att diagnostisera virusburna övre luftvägsinfektioner.
-
The art of building a biologic drug
The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “We do everything in-house ‒ from DNA fragments to a final process,” says David Vikström, Chief Technology Officer at the company.
-
Study: Vaccination linked to lower risk of post-COVID
The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Setback for Moderna in patent dispute with mRNA competitors
Moderna has suffered a setback in a patent battle against their worst competitors in covid vaccines, Biontech and its partner Pfizer.
-
High biological age is linked to a higher risk of dementia and stroke
It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher than their actual age are significantly more likely to suffer from dementia and stroke.
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
Här är medtechbolagen som växer i rekordfart
Intellego Technologies toppar årets lista över Sveriges snabbast växande techföretag. Det Stockholmsbaserade medtechbolaget har ökat sin nettoomsättning med hela 7 723 procent på fyra år.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment line for cancer patients, and the company recently presented positive data from a phase II study.
-
Ny sammanställning: Regionerna ska spara minst 10 miljarder
Flera regioner ser ut att gå med underskott 2023. Enligt en ny enkätundersökning av Sveriges Radio Ekot väntas besparingar i en majoritet av regionerna.
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.
-
Svenskt läkemedel på lista över bästa innovationerna 2023
Svensk innovation finns med när den amerikanska tidskriften Time listar årets bästa innovationer. Alzheimerläkemedlet lecanemab, som utvecklats av svenska Bioarctic, har utsetts som en av de bästa innovationerna 2023 inom kategorin medicinsk vård.
-
Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease
According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases of the aggressive cancer mesothelioma.
BREAKING